25 years of interferon-based treatment of chronic hepatitis C: an epoch coming to an end
25 years of interferon-based treatment of chronic hepatitis C: an epoch coming to an end
复制标题
DOI：
10.1038/nri3463
复制
发表时间：
2013-07-01
影响因子：
100.3
通讯作者：
Heim, Markus H.
中科院分区：
文献类型：
--
作者：
Heim, Markus H.
由丙型肝炎病毒（HCV）感染引起的慢性肝炎（因此称为慢性丙型肝炎（CHC））是全球肝病的主要原因。在过去的25年里，重组干扰素-α（IFN α）一直是治疗HCV感染的主要成分。IFN α的聚乙二醇化及其与其他抗病毒药物联合使用后，治疗效果显示出逐步改善。然而，病毒逃逸机制、肝脏中难治性IFN α信号传导和大量药物毒性仍然限制了这种治疗的功效。新一代HCV特异性抗病毒药物可能会提高应答率，并可能在未来几年内取代干扰素治疗CHC。这篇时间轴文章总结了使用重组IFN α治疗CHC的历史，重点是作用机制和无应答的原因。
Chronic hepatitis caused by infection with hepatitis C virus C (HCV) (therefore known as chronic hepatitis C (CHC)) is a leading cause of liver disease worldwide. For the past 25 years, recombinant interferon-alpha (IFN alpha) has been the main component of treatments for HCV infection. Treatment efficacy has shown a stepwise improvement following the pegylation of IFN alpha and its use in combination with other antiviral drugs. However, viral escape mechanisms, refractory IFN alpha signalling in the liver and substantial drug toxicity still limit the efficacy of this treatment. A new generation of HCV-specific antiviral drugs will probably improve response rates and might replace IFNs in CHC treatment in the next few years. This Timeline article summarizes the history of CHC treatment using recombinant IFN alpha with an emphasis on the mechanisms of action and the causes of non- response.